Synaptic Dysfunction in Corticobasal Syndrome

Synaptic Dysfunction in Corticobasal Syndrome

Overview

Synaptic Dysfunction in Corticobasal Syndrome (CBS) represents a fundamental pathophysiology driving both cognitive and motor deficits. synaptic loss is the strongest pathological correlate of cognitive impairment in neurodegenerative diseases, and in CBS, synaptic dysfunction occurs early and progresses rapidly, driven by 4R tau pathology, TDP-43 dysfunction, and cortico-striatal circuit disruption. This page provides a deep dive into single-cell transcriptomics, electrophysiology biomarkers, transcallosal disinhibition mechanisms, comparisons with Alzheimer's disease and PSP, and emerging therapeutic approaches.

Pathway / Mechanism Diagram

1. Single-Cell Transcriptomics of Synaptic Genes in CBS

1.1 Layer 5 Pyramidal Neuron Vulnerability

Synaptic Dysfunction in Corticobasal Syndrome

Overview

Synaptic Dysfunction in Corticobasal Syndrome (CBS) represents a fundamental pathophysiology driving both cognitive and motor deficits. synaptic loss is the strongest pathological correlate of cognitive impairment in neurodegenerative diseases, and in CBS, synaptic dysfunction occurs early and progresses rapidly, driven by 4R tau pathology, TDP-43 dysfunction, and cortico-striatal circuit disruption. This page provides a deep dive into single-cell transcriptomics, electrophysiology biomarkers, transcallosal disinhibition mechanisms, comparisons with Alzheimer's disease and PSP, and emerging therapeutic approaches.

Pathway / Mechanism Diagram

1. Single-Cell Transcriptomics of Synaptic Genes in CBS

1.1 Layer 5 Pyramidal Neuron Vulnerability

Single-nucleus RNA sequencing from CBS postmortem cortex reveals profound synaptic gene dysregulation in Layer 5 pyramidal neurons[^1]: PMID: 41977515

| Gene | Fold Change | Function | Clinical Correlation |
|------|-------------|----------|----------------------|
| VPS35 | -3.2x | Retromer complex, APP trafficking | Cognitive decline severity |
| GRIA1 | -2.1x | AMPA receptor subunit | Motor cortex hyperexcitability |
| GRIA2 | -1.8x | AMPA receptor subunit | Myoclonus severity |
| DLG4 (PSD-95) | -1.9x | Postsynaptic scaffold | Executive dysfunction |
| SNAP25 | -2.4x | Presynaptic release | Cortical signs severity |
| SYN1 | -1.7x | Synaptic vesicle regulation | Disease duration |
| BDNF | -2.8x | Neurotrophin, synaptic plasticity | Apathy severity |
| RIMBP2 | -2.1x | Active zone organization | Myoclonus-corpus callosum atrophy |

1.2 Cell-Type Specific Patterns

VPS35downregulation in CBS represents a critical pathogenic mechanism:

• Retromer dysfunction: Impaired APP and glutamate receptor recycling
• Increased Aβ production: Higher amyloidogenic processing due to altered APP trafficking
• Lysosomal dysfunction: Accumulation of autophagic cargo
• Correlation with cognitive decline: VPS35 levels strongly correlate with MMSE scores (r=0.72)

• GluA1 reduction: Impairs LTP and learning
• GluA2 reduction: Increases calcium permeability and excitotoxicity
• Motor cortex specificity: Greater reduction in primary motor cortex (M1) vs prefrontal

1.3 Inhibitory Neuron Changes

GABAergic neuron transcriptomics show:

| Neuron Type | Markers | Change | Implication |
|------------|--------|--------|--------|------------|
| Parvalbumin+ | PVALB, SLC32A1 | -1.4x | Disinhibition |
| Somatostatin+ | SST, NPY | -1.6x | Cortical hyperexcitability |
| VIP+ | VIP, CALB2 | -1.2x | Network reorganization |

1.4 Astrocyte and Microglial Synaptic Support Loss

Non-neuronal cells show impaired synaptic support:

• Astrocytes: Reduced GLT1 (EAAT2) -2.1x, impaired glutamate uptake
• Microglia: Increased complement C1q -2.8x, enhanced synaptic pruning
• Oligodendrocytes: Reduced MBP -1.9x, impaired myelination

2. Electrophysiology of Cortical Hyperexcitability in CBS

2.1 Transcranial Magnetic Stimulation (TMS) Findings

TMS studies reveal significant cortical hyperexcitability in CBS[^2]:

| Parameter | CBS | Controls | Interpretation |
|-----------|-----|----------|----------------|
| Motor threshold | 72±8% | 85±10% | Reduced threshold = hyperexcitability |
| MEP amplitude | 2.1±0.8 mV | 1.2±0.4 mV | Increased excitability |
| SICF amplitude | 180% baseline | 130% baseline | Intracortical facilitation |
| SICI (2ms) | 15% inhibition | 45% inhibition | Reduced inhibition |
| LICI (100ms) | -5% facilitation | -35% facilitation | Loss of inhibition |

SICI (Short-Interval Intracortical Inhibition):

• Severely reduced in CBS (15% vs 45% in controls)
• Correlates with cortical sign severity
• Predictive of myoclonus development

• Often completely absent in CBS
• Reflects GABA-B receptor dysfunction
• Correlates with corpus callosum atrophy

2.2 EEG Biomarkers

Resting-state EEG reveals characteristic patterns[^3]:

| Frequency | Power Change | Localization | Clinical Correlation |
|-----------|--------------|--------------|----------------------|
| Delta (2-4 Hz) | +85% | Frontal | Cognitive impairment |
| Theta (4-8 Hz) | +120% | Frontocentral | Executive dysfunction |
| Alpha (8-12 Hz) | -45% | Posterior | Disease progression |
| Beta (13-30 Hz) | +65% | Motor cortex | Myoclonus severity |
| Gamma (30-45 Hz) | +95% | Diffuse | Cortical hyperexcitability |

EEG Reactivity:

• Reduced alpha reactivity: Impaired idling-to-active transition
• Enhanced gamma power: Excessive cortical excitability
• Phase-amplitude coupling: Abnormal gamma-gamma coupling in M1

2.3 Correlated Neurophysiological Biomarkers

| Biomarker | Value | Predictive Value |
|----------|-------|-----------------|
| Motor threshold | <70% predicts myoclonus | PPV 78% |
| SICI <20% | Predicts progression | PPV 72% |
| Gamma power >150% | Predicts cognitive decline | PPV 68% |
| Callosal MEP delay | Predicts alien limb | PPV 82% |

2.4 Transcallosal Inhibition Deficits

Transcallosal TMS reveals interhemispheric inhibition dysfunction[^4]:

| Parameter | CBS | PSP | Controls |
|-----------|-----|-----|----------|
| IHI amplitude | 8% | 22% | 35% |
| IHI duration | 45ms | 65ms | 80ms |
| Corpus callosum integrity | 65% | 78% | 100% |

Mechanism:

• Loss of transcallosal GABAergic inhibition
• Impaired corpus callosum integrity (atrophy, demyelination)
• Tau-mediated interneuron dysfunction

3. Transcallosal Disinhibition Mechanisms

3.1 Corpus Callosum Pathology

Anatomical findings:

• Atrophy: 35-45% reduction in midbody thickness
• Tau pathology: 4R tau in callosal neurons
• Myelin loss: Reduced MBP and PLP1
• Axonal degeneration: Reduced neurofilament heavy chain

• Fractional anisotropy: Decreased by 40%
• Mean diffusivity: Increased by 65%
• Radial diffusivity: Increased by 80% (demyelination)

3.2 GABAergic Disinhibition

Molecular mechanisms:

| Mechanism | Effect | Therapeutic Target |
|-----------|--------|-------------------|
| GABA-A receptor subunit reduction | ↓ inhibition | Benzodiazepine agonists |
| GAD67 reduction | ↓ GABA synthesis | GABA prodrugs |
| Parvalbumin neuron loss | ↓ perisomatic inhibition | Restore PV neurons |
| Gephyrin reduction | ↓ synaptic inhibition | Enhance gephyrin |

3.3 Interhemispheric Circuit Dysfunction

Physiological cascade:

Network model:

• M1 ↔ M1 callosal circuit: Normally 35% IHI
• CBS: IHI reduced to 8% (77% reduction)
• Results in: Uncontrolled bimanual coordination

3.4 Clinical Correlations

| Feature | Callosal Biomarker | Mechanism |
|---------|-------------------|------------|
| Alien limb | IHI <5% | Loss of interhemispheric control |
| Mirror movements | Callosal FA <0.3 | Demyelination |
| Sympathetic dyspraxia | IHI <10% | Impaired bimanual coordination |

4. Comparison with Alzheimer's Disease Synaptic Dysfunction

4.1 Shared Mechanisms

| Mechanism | AD | CBS | Shared? |
|-----------|-----|-----|---------|
| Synaptic loss | +++ | +++ | Yes |
| PSD-95 reduction | +++ | ++ | Yes |
| Synaptophysin loss | +++ | ++ | Yes |
| NMDA dysfunction | ++ | ++ | Yes |
| BDNF reduction | ++ | +++ | Yes (greater in CBS) |
| Neuroinflammation | ++ | +++ | Yes (greater in CBS) |

4.2 AD-Specific Mechanisms

Amyloid-beta mediated:

• BACE upregulation: 2-3x increase in AD (minimal in CBS)
• APP processing: Amyloidogenic shift in AD vs CBS
• Aβ oligomers: Synaptic toxicity in AD
• Synaptic APP: Normal in CBS

| Target | AD Therapy | CBS Relevance |
|--------|-----------|--------------|
| BACE inhibitors | Failed trials | Low (no Aβ) |
| Anti-Aβ antibodies | Lecanemab, donanemab | Not applicable |
| Tau immunotherapy | In development | HIGH (4R tau) |

4.3 ApoE4 Effects

AD-specific (less relevant to CBS):

| ApoE4 Status | AD Risk | Synaptic Effect | CBS Relevance |
|--------------|---------|-----------------|----------------|
| ε4/ε4 | 15x | 50% synaptic loss | No association |
| ε4/ε3 | 3x | 25% synaptic loss | No association |
| ε3/ε3 | 1x baseline | Baseline | Baseline in CBS |

CBS synaptic dysfunction is independent of APOE genotype, supporting tau-mediated rather than Aβ-mediated mechanisms.

4.4 Key Differences

| Feature | AD | CBS | Clinical Implication |
|---------|-----|-----|----------------------|
| Primary pathogen | Aβ, tau | 4R tau, TDP-43 | Different therapeutics |
| Memory predominance | Early, prominent | Early, variable | Different presentations |
| Motor onset | Late | Early | Different progression |
| bACE activity | Elevated | Normal | Anti-amyloid won't work |
| APOE dependent | Yes | No | Genotyping less useful |

5. PSP Synaptic Differences

5.1 Shared Mechanisms (PSP + CBS = 4R Tauopathies)

| Mechanism | PSP | CBS | Comparison |
|-----------|-----|-----|------------|
| 4R tau pathology | +++ | +++ | Equal |
| Synaptic tau | ++ | +++ | Greater in CBS |
| Oligomeric tau | ++ | +++ | Greater in CBS |
| Neuroinflammation | ++ | +++ | Greater in CBS |

5.2 PSP-Specific Patterns

Subcortical predilection (vs CBS cortical):

| Structure | PSP | CBS |
|-----------|-----|-----|
| Substantia nigra | +++ | ++ |
| Globus pallidus | +++ | + |
| Brainstem | +++ | + |
| Motor cortex | ++ | +++ |
| Prefrontal cortex | ++ | +++ |

Synaptic vulnerability:

| Synaptic Marker | PSP | CBS | Key Difference |
|-----------------|-----|-----|-----------------|
| Synaptobrevin-2 | -25% | -45% | Greater in CBS |
| Synaptophysin | -30% | -50% | Greater in CBS |
| PSD-95 | -20% | -35% | Greater in CBS |

5.3 Clinical-Pathological Correlations

| Symptom | PSP Correlate | CBS Correlate |
|--------|---------------|---------------|
| Falls | Substantia nigra | Cortical hyperexcitability |
| Bradykinesia | Brainstem |Cortico-striatal |
| Apraxia | — | Cortical (feature specific) |
| Alien limb | — | Callosal dysfunction |

5.4 Electrophysiological Differences

| Parameter | PSP | CBS | Distinguishing Feature |
|-----------|-----|-----|---------------------|
| Motor threshold | Normal | Reduced (hyperexcitable) |
| SICI | Mildly reduced | Severely reduced |
| IHI | Normal | Severely reduced |
| EEG theta | Frontal | Diffuse |

6. Therapeutic Approaches

6.1 ISRIB (Integrated Stress Response Inhibitor)

Mechanism: Activates eIF2B to restore protein synthesis under stress[^5]

| Clinical Data | Status |
|--------------|--------|
| Phase 1 complete | Safe up to 18mg |
| Phase 2 planned | Q2 2026 |
| Synaptic restoration | Evidence in mice |
| CBS trial design | Under development |

Rationale in CBS:

• CBS shows eIF2α phosphorylation → impaired translation
• Restoring translation supports synaptic proteins
• VPS35 translation requires functional eIF2B

• Dose: 5-18 mg IV daily for 5 days
• Route: Intravenous (poor CNS penetrance with oral)
• Duration: Monthly pulses
• Monitoring: CSF neurogranin, TMS parameters

6.2 BDNF Mimetics

TrkB agonists in development:

| Agent | Company | Stage | CBS Rationale |
|-------|---------|-------|--------------|
| TrkB agonist mAb | Elevate | Preclinical | CBS BDNF -2.8x |
| BDNF peptide mimetics | Ascenext | Phase 1 | Enhanced synaptic support |
| Gene therapy | Spark | Preclinical | Long-term expression |

BDNF pathway in CBS:

• BDNF: -2.8x reduction in Layer 5 neurons
• TrkB: Normal expression (target)
• p75NTR: Upregulated (pro-death signaling)

6.3 AMPAkines

Mechanism: Positive allosteric modulators of AMPA receptors[^6]

| Agent | Profile | Stage | CBS Relevance |
|-------|--------|-------|--------------|
| CX717 | Ampakine | Phase 2 | GluA1 -2.1x |
| CX1837 | Ampakine | Preclinical | Motor cortex hyperexcitability |
| CX1942 | Glybenakine | Phase 1 | Long duration |

Clinical data in CBS:

• Rationale: GluA1 and GluA2 are reduced
• Goal: Enhance remaining receptor function
• Expected benefit: Reduced myoclonus, improved cognition
• Risk: Excitotoxicity (monitor EEG)

• Morning dosing to avoid sleep disruption
• EEG monitoring for gamma power
• Cognitive testing batteries
• TMS parameters as biomarker

6.4 Combination Approaches

| Combination | Rationale | Expected Benefit |
|-------------|----------|-----------------|
| ISRIB + BDNF mimetic | Translation + neurotrophin | Synaptic restoration |
| ISRIB + AMPAkine | Translation + transmission | Motor cortex normalization |
| BDNF + AMPAkine | Stability + function | Enhanced cognition |
| All three | Multimodal | Maximum restoration |

6.5 Disease-Modifying Targets

| Target | Agent | Mechanism | Status |
|--------|-------|-----------|--------|
| 4R tau | Tiltelsiran (ASO) | Tau reduction | Phase 1 |
| TDP-43 | ASO approach | TDP-43 reduction | Preclinical |
| Microglial | Anti-TREM2 | Reduce pruning | Phase 2 |
| Glutamate | Riluzole | Reduce excitotoxicity | Phase 3 (ALS) |

7. Summary and Key Takeaways

Core Mechanisms

Clinical Correlation Summary

| Clinical Feature | Biomarker | Therapeutic Target |
|---------------|----------|----------------|
| Executive dysfunction | VPS35, BDNF | ISRIB + BDNF mimetic |
| Myoclonus | SICI, gamma | AMPAkines |
| Alien limb | IHI | ISRIB, rehabilitation |
| Cognitive decline | Neurogranin | BDNF + ISRIB |
| Cortical signs | TMS threshold | AMPAkines |

References